SynthesisMolecular biology reports2025
The dual role of miR-184 in cancer: a systematic review of context-dependent regulation.
Synthesis in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Circulating and Tissue MicroRNA Profiles Associated with Pathological Complete Response in HER2+ Breast Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA-184 (miR-184) regulates gene expression by binding to target messenger RNAs, promoting their degradation, and influencing key cellular processes. Its role in human cancers is complex: while several studies report tumour-suppressive effects, including inhibition of proliferation, migration, and metastasis, contradictory evidence indicates that miR-184 may act as a tumour promoter in certain contexts. This systematic review aimed to clarify whether miR-184 functions as a universal anticancer agent across human cancers. A comprehensive search of PubMed and SCOPUS identified 123 records, of which 55 studies met inclusion criteria. Analysis revealed that miR-184 predominantly acts as a tumour suppressor in cancers such as prostate and breast, whereas in liver and bone cancers, it exhibits tumour-promoting activity. Certain cancer types, including skin and pancreatic cancers, showed inconsistent or context-dependent effects. Key molecular targets and pathways influenced by miR-184, including c-MYC, caspases, and apoptotic signalling, were highlighted. Overall, these findings demonstrate that the function of miR-184 in cancer is context-dependent, shaped by tissue type, molecular environment, and cellular signalling networks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.